Safety, Tolerability, and Pharmacodynamics of SYNB8802v1 in Subjects With History of Gastric Bypass Surgery or Short-bowel Syndrome

NCT05377112 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

11

Enrollment

INDUSTRY

Sponsor class

Conditions

Enteric Hyperoxaluria

Interventions

DRUG: SYNB8802v1
OTHER: Placebo

Sponsor

Synlogic